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Smman- Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to
136 patients in five different regimens. The total response rate was 32%o (95% confidence interval 24-400o):
13% had a complete remission. Female patients had a significantly higher chance of response than male
patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%O. The overall survival
was 6 months: 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although
response rates vary among the various regimens described in the literature. the complete response rates are
quite similar and the long-term disease-free survival of these combinations mav be similar to that of
dacarbazine alone.
Treatment of patients with disseminated malignant
melanoma remains unsatisfactory. Options under study in-
clude no treatment. biological therapy. chemotherapy or
combinations of both.
Often short-term evaluations. focusing only on response
rates. are used to direct further studies or to influence treat-
ment outside the clinical trial situation. However, as re-
sponses are usually short-lived and occur in non-symptomatic
lesions, they are unlikely to have much influence on survival
or on quality of life. For many years dacarbazine (DTIC) has
been the mainstay of chemotherapy in this stage of disease.
mainly because of the lack of demonstrated superiority of
any other agent or combination.
We have over a 7 year period used this drug as part of
various combination regimens in 136 consecutive patients
with disseminated malignant melanoma (Mulder et al.. 1986.
1989. 1990. 1992: Buter et al.. 1994). We report here the
short-and long-term outcome of these studies, to provide a
measure against which other treatment options can be
assessed.
Patients and methods
Five different regimens were used consecutively:
Regimen I Dacarbazine 300mgm~- on 4 consecutive
days combined with continuous infusion of
bleomycin 30 mg day-', followed on day 5 by
vindesine 3 mg m- and actinomycin D
2 mg m-'. Cycles were repeated every 4 weeks
(Mulder et al., 1986).
Regimen II The same regimen without actinomycin D
(Mulder et al., 1989).
Regimen III DTIC 750mgm-- on day 1 and alpha-inter-
feron 9 mU daily for 21 days. given for six
cycles in responding patients (Mulder et al..
1990).
Regimen IV DTIC 750mgm-- on day 1 and alpha-inter-
feron 9 mU given for 28 days, on day 14
5-fluorouracil (5-FU) 1.00 mg m--, six cycles
(Mulder et al.. 1992).
Regimen V DTIC 750-1,500 mg m-- on day 1 and alpha-
interferon 9 mU for 21 days, repeated every 3
weeks, combined with daily granulocyte
colony-stimulating factor (G-CSF) (Buter et
al.. 1994).
Patients
Patients with a histological diagnosis of malignant
melanoma. who had not received previous chemotherapy.
without clinical evidence of central nervous system involve-
ment and without hyperbilirubinaemia were entered into the
study. The age limit was set at 75. All patients had disease
shown to be progressive within the last 6 months. Entry into
these studies required evaluable or measurable disease.
Assessment of response and toxicity was done according to
WHO criteria. Survival was measured from the start of
chemotherapy. response duration from the moment response
was diagnosed.
Results
One hundred and thirty-six patients were entered. 82 male
and 54 female. Their median age was 47 years (range
17-74).
Patients entered into the five regimens and their charac-
teristics are given in Table I. The complete and partial re-
sponse rates, the number of patients responding for more
than 6 months and the number of patients surviving disease
free for more than 2 years are given in Table II. as well as
the relation with sex.
The total number of responders is 44 or 32% (95% con-
fidence interval 24-40%); of these 18 or 13% had a complete
response. There is no significant difference between the
various regimens. The response rate is. however, dependent
on gender: the response rate in female patients is 25 out of 54
or 46% and in males is 230% (7 = 7.96. P = 0.004). In com-
plete responders this difference is also significant: 25% vs 9%
in males (i' = 3.97. P= 0.04). Responses are also much more
common in the lung (39%) and lymph nodes (30%) than in
the liver (2%) (Table III).
In the responding patients 11 responses lasted for more
than 6 months (25%). Overall, in all patients treated. the
chance of such a prolonged response is 8% (95% confidence
Table I Patient characteristics
Number of Sex Median age (range)
Regimen patients M F (vearsi
1 27 14 13 43 (24- 59)
II 31 2110 47 (24-69)
III 31 18 13 51 (17-74)
IV 26 1511 44 (15-57)
V' 21 147 47 (30-68)
Total 136 82 54 47 (17-74)
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Table II
Rem Rem
Regimen PR (.Uf F} CR (AM F} .UST >6 months >2 years
1 5 05 4 22 5 1 1
II 5 2 3 5 2 3 5 2 1
III 8 6 2 3 1 2 6 6 0
IV 5 3 2 5 23 12 2
V 3 1 21 0 1 7 0 0
Total 26 12 14 18 711 6 11 4
PR. partial response: CR. complete response; Rem. remission duration; MST. median
survival time in months.
Table III Remission in individual metastatic sites
Site Number ofpatients Number ofremissions
Lung 64 25
Lymph nodes 23 7
Subcutaneous 52 15
Bone 7 1
Liver 35 1
Spleen 1 0
Adrenal 1 0
Submucosal 1 0
Cutaneous 13 0
level 4-14%). Four patients have a disease-free survival after
chemotherapy of more than 2 years: 2% of all patients
treated, 9% of responders and 22% of all complete re-
sponders. However, half of these patients have relapsed,
leaving one patient disease free after 3 years and one after 7
years, possibly cured (0.7%).
The median survival of all patients is 6 months; only
regimen IV has a longer survival ofmedian 12 months (Table
II).
The toxicity of these regimens has changed dramatically
over the treatment period: nausea and vomiting were dose
limiting prior to the advent of serotomnn antagonistic drugs,
but have been virtually eliminated since. Grade 3 or 4 toxi-
city occurred in 24 patients, in one mucositis (on actinomycin
D), in the others leuco- and thrombopenia; in seven patients
toxicity occurred on the DTIC dose escalation regimen
(regimen V).
Dicussion
The results of these studies emphasise the problems in the
treatment of metastatic melanoma. The chances of prolonged
survival are small. In this study only one patient appears to
have achieved cure. It has often been questioned whether
response has any correlation at all with survival (Balek et al.,
1983; Ahmann et al.. 1989). However, in contrast to those
reports, we found no long-term survivors among non-re-
sponders. This could be a result of selection of patients with
progressive disease in our studies.
Compared with the results of monotherapy with DTIC.
combination therapy is associated with considerable toxicity
for a marginal benefit. The response rate of DTIC alone is
reported to be 20%, with a complete response rate of 5%.
Long-term survival is 2% (Hill et al.. 1984). These results are
somewhat. but not much, lower than found in this study. In
view of its limited extramedullary toxicity. DTIC can be
combined with any drug. The regimens used in this study
were inspired by presumed synchronised effects (regimens I
and II) or synergy (regimens III and V). Recently, a ran-
domised study found that response duration was increased by
some months when interferon was added to DTIC (Bajetta et
al., 1994). In view of the somewhat longer survival with the
addition of 5-FU (Table II), this combination might deserve
some further attention.
In general, combination therapy with DTIC. such as the
regimens described here or combinations with tamoxifen.
cisplatin and nitrosurea, is associated with somewhat higher
response rates than monotherapy. Complete response rates
hover around 10%. but translation into long-term survival is
doubtful. In the occasional reports recording responses of
50% or higher, it is usually the partial response rate rather
than the complete response rate that is increased (Pyrh6nen
et al., 1992).
A striking observation in this and some other studies is the
much better response rate for women (Presant & Bartolucci,
1982; Luger et al.. 1990), a difference that cannot easily be
explained.
Given the toxicities of combination chemotherapy or inter-
feron and interleukin 2. a case can be made for mono-DTIC
treatment as a first choice outside the setting of a clinical
tnal, especially since nausea has almost been abolished.
Selection of patients with favourable prognostic cnrtenra. such
as female sex and predominant lung metastasis, could result
in a fair response rate at the cost of limited toxicity.
Other regimens based not on presently available drug com-
binations but on new technologies such as specific immunisa-
tion or gene transfer seem to be required for an impact on
overall survival.
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